To Get Rich, Go Small

It’s like science, but it doesn’t crush your soul. April 30, 2024 [WEBSITE]( | [UNSUBSCRIBE]( DeSci’s rise could be closer than you think… and the potential upside is immense. To Get Rich, Go Small CHRIS CAMPBELL Dear Reader, Yesterday, we explored how technology acts as a powerful amplifier, magnifying the impact of any system it's applied to. When the underlying system is sound, the results can be revolutionary. But when it's riddled with flaws, the consequences can be disastrous as a heated paintball tournament at a nudist colony. For example… The rise of powerful AI language models like ChatGPT is exposing deep cracks in the scientific establishment -- from rampant fraud and sloppy methodology to perverse incentives that prioritize publishing over rigorous research. Thankfully, the shedding of this long, dark veil will lead to a thirst for more transparency, more truth, and more (wait for it) science. I suspect it will lead to more citizen science, which social media has already helped to facilitate. iNaturalist, for example, is an app and social network that allows users to photograph and share plants, animals, and organisms in their areas, contributing to a global database that helps scientists track biodiversity. Zooniverse is a citizen science network that leverages volunteers in tasks ranging from classifying galaxies to transcribing medieval texts. After the Fukushima nuclear disaster, Safecast leveraged social media to gather and share radiation measurements from volunteers using Geiger counters across Japan. This created a crowd-sourced map of radiation levels, providing transparent data that was not otherwise available. And then there’s DeSci -- the final piece of the puzzle -- leveraging the power of immutable ledgers and AI to realign incentives and accelerate discovery. How does DeSci plan to do so, you ask? It’s simple. Science As it Should Be At its core, DeSci is about two things: permissionless provenance and participatory capital formation. Provenance just means tracking the origin and history of something. Permissionless means anyone can use and access those records without needing approval from gatekeepers. By timestamping lab data and publishing results to blockchains in real-time, researchers can prove conclusively that their work came first. No more hiding findings in fear of getting scooped. No more disputes over authorship and attribution. With provenance assured, scientists are free to embrace the kind of open, collaborative approach that's key to scientific progress. No more politics in research. Furthermore, participatory capital formation means creating new ways for anyone to fund scientific research. Instead of relying solely on volunteers and grants from governments or big institutions, DeSci platforms allow researchers to crowdfund support from individuals worldwide who share their interests. Imagine a biotech startup issuing "lab tokens" that give holders a stake in the IP they produce. Or a Zooniverse-like platform that pays individuals for completing microtasks in a global research database. Or a DAO (decentralized autonomous organization) where members vote on which research projects to back with the group's pooled funds. By aligning incentives between researchers and supporters, DeSci encourages greater accountability and focus on delivering real-world impact. A few projects are leading the charge: VitaDAO and PsyDAO allow token holders to vote on grant allocations for research projects in longevity science and psychedelic medicine respectively. Meanwhile, Molecule and LabDAO leverage IP-NFTs and quadratic funding to launch biotech ventures and crowdfund experiments. While still early stage, these examples demonstrate how Web3 primitives like tokens, NFTs and DAOs can create new markets and funding mechanisms to support scientific innovation in more open, accessible, and rewarding ways. Especially when compared to the traditional grant-based or closed-door venture models. Meanwhile, AI's potential impacts on the scientific process itself cannot be overstated, either. [CRITICAL: U.S. Gov’t Agency To Trigger Massive Move In The AI Market?]( A Nobel Prize winner and doctors from Harvard, Yale, Stanford, and Johns Hopkins have just unveiled a shocking new type of discovery… Due to this similar discovery, this tiny $6-stock AI companymight have stumbled upon the biggest cancer discovery in history. And in as little as a few short days, we expect the FDA could deliver a bombshell announcement regarding this company and its work, triggering a historic move in the AI market. [Click here now for the full story.]( Crypto x AI Tools like DeepMind's AlphaFold are solving grand challenges like protein folding in a fraction of the time humans can. Language models help researchers efficiently parse millions of studies, while other AI systems can propose more promising hypotheses and automatically design optimal solutions to engineering problems. Before long, we’ll have fleets of AI-powered robotic labs sharing data in an open marketplace for other labs to build upon. This is where crypto and AI find a natural fit: Two major blockchain players are creating decentralized marketplaces for AI algorithms and datasets. (One of them is well-known to our Altucher’s Investment Network readers.) Through these protocols, researchers can monetize their AI tools and data by offering them for use by others through these platforms. This incentivizes open sharing of valuable AI resources for scientific applications, while keeping proprietary data private. Of course, major hurdles remain before this techno-optimist vision of the scientific future materializes. But it could be closer than many think… and the potential upside is immense. More tomorrow. Of course, investing in this trend effectively is tricky. Fortunately, our own Paradigm colleague Ray Blanco is already three steps ahead on the AI front. To Get Rich, Go Small In as little as a few short days, our Paradigm colleague Ray Blanco expects the FDA could deliver a bombshell announcement regarding a small AI company with a stock sitting at about $6. As is usually the case… The world’s richest billionaires (like Bill Gates and his foundation) have already staked their claim in this tiny stock. The key thing that Ray uncovered that makes this story so explosive is this: Big Pharma companies quietly pony up millions to access this AI platform and use it for new drugs. This includes almost ALL of the big names in the industry. Best part? The market hasn’t caught up to this story. The company’s stock is still sitting at about $6. Ray tells you everything you need to know about this company in a brand new interview: [Click the link to get the full scoop from Ray.]( Until tomorrow, Chris Campbell For Altucher Confidential Rate this email Like Dislike Thanks for rating this content! Looks like something went wrong. Please try to rate again. [Urgent Notice About Your Access]( We just announced a massive new change to Altucher’s Investment Network, and as one of our loyal readers, we want to make sure you know what’s going on. [Click here]( to secure your access now. ☰ ⊗ [ARCHIVE]( [ABOUT]( [Contact Us]( © 2024 Paradigm Press, LLC. 1001 Cathedral Street, Baltimore, MD 21201. By submitting your email address, you consent to Paradigm Press, LLC. delivering daily email issues and advertisements. To end your Altucher Confidential e-mail subscription and associated external offers sent from Altucher Confidential, feel free to [click here.]( Please note: the mailbox associated with this email address is not monitored, so do not reply to this message. We welcome comments or suggestions at feedback@altucherconfidential.com. This address is for feedback only. For questions about your account or to speak with customer service, [contact us here]( or call (844)-731-0984. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular investment situation. No communication by our employees to you should be deemed as personalized financial advice. We allow the editors of our publications to recommend securities that they own themselves. However, our policy prohibits editors from exiting a personal trade while the recommendation to subscribers is open. In no circumstance may an editor sell a security before subscribers have a fair opportunity to exit. The length of time an editor must wait after subscribers have been advised to exit a play depends on the type of publication. All other employees and agents must wait 24 hours after on-line publication or 72 hours after the mailing of a printed-only publication prior to following an initial recommendation. Any investments recommended in this letter should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Altucher Confidential is committed to protecting and respecting your privacy. We do not rent or share your email address. Please read our [Privacy Statement.]( If you are having trouble receiving your Altucher Confidential subscription, you can ensure its arrival in your mailbox by [whitelisting Altucher Confidential.](